“LLMs are economically and practically unsuited to the tasks they’ve promised to solve, and no amount of extra capital expenditures or venture capital dollars will magically fix that.”
Our reading, the sentence that was checked:
LLMs are economically and practically unsuited to their promised tasks, and more capex or VC money will not fix that.
Assessment: Unresolved No deadline stated on 2026-10-29 Evidence as of
Where and when Ed Zitron wrote it
Where's Your Ed At, The More You Buy, The More You Lose, paragraph 137.
- Said
- Source observed
- live page, full text, public
- Evidence as of
- the cutoff for this assessment
- Assessment recorded
- assessment wyea-the-more-you-buy-the-more-you-lose-27fb9b-a1
We recorded 33 claims from this post. See every claim from this post.
The wording above is the version this site observed on 2026-10-28. The source may have been edited after 2026-07-28. This page does not claim the wording was captured then.
What the claim commits to
- Kind
- Forecast
- Deadline, as the speaker wrote it
- None stated. This site does not add one.
- Deadline state when assessed
- No deadline stated
- Deadline state on 2026-10-29
- No deadline stated (the release’s reference date)
From the speaker
- LLMs
- economically and practically unsuited
- the tasks they’ve promised to solve
- no amount of extra capital expenditures or venture capital dollars
- will magically fix that
Our interpretation
- Read as a categorical prediction that further investment cannot make LLMs reliably useful and economically viable for substantive promised work. Treat 'magically' as rhetorical emphasis.
- The surrounding passage acknowledges coding, search, brainstorming and document retrieval. Success confined to those acknowledged uses is not sufficient to settle this broader prediction.
- Economic suitability means benefits justify the costs of providing and using the system, including human oversight and correction. It does not require every model supplier to become profitable.
- The speaker supplies no task list, reliability threshold, economic measure or deadline. Task-specific requirements and comparisons with existing methods are necessary evaluator choices.
- Assess the forward-looking commitment as supplied, rather than separately grading the present-tense assertion.
Counts as supported if: Evidence establishing a persistent technical or economic constraint that further investment cannot overcome for the relevant promised work would support the categorical prediction. Current failures, losses or disappointing trials alone cannot establish permanent impossibility.
Counts as contradicted if: A credible, reproducible demonstration after further investment that LLMs reliably perform substantive promised work beyond the acknowledged uses, with benefits exceeding the full costs of delivery, oversight and correction, would contradict the categorical prediction.
Retrospective: these criteria were written after the outcome was public.
Current assessment
Did the forecast come true?
Outcome: Unresolved
The record was checked, and the evidence available by the cutoff does not settle it.
Scored on a plain reading. The speaker named no measure for this claim, so it was judged on the reading an informed reader would take, stated below under our interpretation. Both reviews had to find that reading fair.
- Evidence as of
- Deadline state when assessed
- No deadline stated
- Assessment recorded
- Policy version
- 2026-10-28.7
Rationale
The claim has no deadline. The clinical trial shows a limitation in one application, while the production study reports improving reliability and the benchmark shows that oversight requirements vary across systems. These findings neither prove permanent unsuitability nor establish a decisive, economically viable deployment after further investment. None meets the early-resolution rule. The forecast therefore remains unresolved as of October 28, 2026.
Limitations
- The undefined tasks and economic standard materially affect what would count as a counterexample.
- The production reliability evidence is a preprint; the deployment framework is a vendor-produced benchmark.
- The retrieved clinical text was limited to its abstract despite being marked FULL TEXT.
- This assessment does not separately score the claim's present-tense component.
Evidence (3 items)
Context only: Nature Medicine,
The primary outcome did not differ significantly between groups.
Why it matters here: This randomized trial enrolled patients between April and July 2025 and found no significant reduction in treatment failure with LLM assistance. That is evidence of a limitation in one setting, not evidence that future investment cannot improve performance.
- Publisher
- Nature Medicine
- Kind of source
- Peer-reviewed paper
- Describes events of
- Public from
Context only: arXiv,
Reliability also shifted materially across logged deploys.
Why it matters here: The study reports improving measured reliability from March through August 2026 and declining interview-related support tickets in a deployed interviewing agent. This weighs against fixed practical incapacity, but does not establish sufficient absolute reliability, full economic viability or an effect of additional investment.
- Where
- Abstract
- Publisher
- arXiv
- Kind of source
- Preprint, not peer reviewed
- Describes events of
- Public from
Context only: Scale Labs,
Systems with nearly identical autonomous performance can support substantially different reliability–oversight tradeoffs.
Why it matters here: The announced framework evaluates reliability alongside oversight and operating cost, with a clinical-audit case study showing different oversight requirements for similar autonomous accuracy. Qualification at its chosen reliability target does not establish sustainable real-world economics or fulfillment of the unspecified promises.
- Publisher
- Scale Labs
- Kind of source
- Benchmark result
- Describes events of
- Public from
What would settle it
A dated, independently verifiable deployment after further investment that performs an identified promised task reliably and delivers benefits above full delivery, oversight and correction costs could contradict the prediction. Further failures alone would not prove its unlimited negative.
Where it was said (1)
Said once in the sources this register covers.
: Where's Your Ed At, The More You Buy, The More You Lose
LLMs are economically and practically unsuited to the tasks they’ve promised to solve, and no amount of extra capital expenditures or venture capital dollars will magically fix that.
- Where
- paragraph 137
- Published
- 2026-07-28
- Source observed
- , live page
- Access
- full text, public
History
Assessment versions
- Assessment wyea-the-more-you-buy-the-more-you-lose-27fb9b-a1: Current. Outcome: Unresolved. Evidence as of 2026-10-28. Public date not recorded.
Recorded events
Assessment publishedBy this site
First assessment published after both reviews and the final-text check passed.
About assessment wyea-the-more-you-buy-the-more-you-lose-27fb9b-a1.